基本信息
浏览量:218
职业迁徙
个人简介
His research interest during the early period was in the molecular mechanism of cancer metastasis. Then, in 1999 Dr. Yamori established a panel of 39 human cancer cell lines (JFCR39) for the purpose of discovery of molecular targeted-drugs. Since then, he had expanded his expertise in the field of drug discovery and molecular pharmacology(1). Based on the unique JFCR39 system, he identified novel anticancer compounds including a topoisomerase inhibitor (MS-247)1, a telomelase inhibitor (FJ5002)2, a PI3-kinase inhibitor (ZSTK474)3 and a Golgi disruptor (AMF-26)4. Among them, ZSTK474 is under clinical development. IHe presently works on the evaluation of new drugs, biologics and medical devices, and also participates in the development of regulatory science. He published 197 peer-reviewed articles and more than 70 Japanese reviews in the field of biology and treatment of cancer.
研究兴趣
论文共 351 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2023)
openalex(2023)
crossref(2023)
crossref(2023)
crossref(2023)
加载更多
作者统计
#Papers: 351
#Citation: 15258
H-Index: 64
G-Index: 112
Sociability: 7
Diversity: 1
Activity: 0
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn